Below are the most recent publications written about "Scleroderma, Systemic" by people in Profiles.
-
Moezinia C, Wong V, Watson J, Nagib L, Lopez Garces S, Zhang S, Ahmed Abdi B, Newton F, Abraham D, Stratton R. Autoantibodies Which Bind to and Activate Keratinocytes in Systemic Sclerosis. Cells. 2023 10 20; 12(20).
-
Nam K, Mendoza FA, Wessner CE, Allawh TC, Forsberg F. Ultrasound quantitative assessment of ventral finger microvasculopathy in systemic sclerosis with Raynaud's phenomena: a comparative study. RMD Open. 2023 02; 9(1).
-
Piera-Velazquez S, Dillon ST, Gu X, Libermann TA, Jimenez SA. Aptamer proteomics of serum exosomes from patients with Primary Raynaud's and patients with Raynaud's at risk of evolving into Systemic Sclerosis. PLoS One. 2022; 17(12):e0279461.
-
Abdellatief A, Balasubramaniam SC, Grube TJ, Gonzalez Santiago TM, Osborn TG, Pulido JS. Indocyanine green angiographic evidence of choroiditis in scleroderma. Retin Cases Brief Rep. 2015; 9(3):231-4.
-
Derrett-Smith EC, Dooley A, Gilbane AJ, Trinder SL, Khan K, Baliga R, Holmes AM, Hobbs AJ, Abraham D, Denton CP. Endothelial injury in a transforming growth factor ß-dependent mouse model of scleroderma induces pulmonary arterial hypertension. Arthritis Rheum. 2013 Nov; 65(11):2928-39.
-
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov 1; 72(11):1747-55.
-
Bryson T, Sundaram B, Khanna D, Kazerooni EA. Connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonia: similarity and difference. Semin Ultrasound CT MR. 2014 Feb; 35(1):29-38.
-
Maurer B, Distler A, Dees C, Khan K, Denton CP, Abraham D, Gay RE, Michel BA, Gay S, Hw Distler J, Distler O. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis. 2013 Dec; 72(12):2039-46.
-
Lee CG, Herzog EL, Ahangari F, Zhou Y, Gulati M, Lee CM, Peng X, Feghali-Bostwick C, Jimenez SA, Varga J, Elias JA. Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-ß1 signaling. J Immunol. 2012 Sep 1; 189(5):2635-44.
-
Mendoza FA, Keyes-Elstein LL, Jimenez SA. Systemic sclerosis disease modification clinical trials design: quo vadis? Arthritis Care Res (Hoboken). 2012 Jul; 64(7):945-54.